UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040138
Receipt number R000045754
Scientific Title Neural basis of therapeutic intervention in neurodevelopmental disorders
Date of disclosure of the study information 2020/04/14
Last modified on 2021/12/10 09:48:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Neural basis of therapeutic intervention in neurodevelopmental disorders

Acronym

Neural basis of therapeutic intervention in neurodevelopmental disorders

Scientific Title

Neural basis of therapeutic intervention in neurodevelopmental disorders

Scientific Title:Acronym

Neural basis of therapeutic intervention in neurodevelopmental disorders

Region

Japan


Condition

Condition

Attention-Deficit/Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)

Classification by specialty

Psychiatry Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study is to investigate neural basis of therapeutic interventions such as medication and group therapy for neurodevelopmental disorders including ASD and ADHD. For this purpose, MRI and clinical / cognitive data are longitudinally evaluated before and after a treatment in clinical practice. MRI data include fMRI, resting-state fMRI, structural MRI and Diffusion Tensor Imaging (DTI).

Basic objectives2

Others

Basic objectives -Others

Brain Information

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

MRI data (fMRI, resting-state fMRI, structural MRI, and DTI)

Key secondary outcomes

Clinical and Cognitive data


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

15 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. ASD and ADHD patients diagnosed by specialists based on DSM-5. Typically developed healthy subjects who agree to participate in this study.
2. Subjects who did not have any serious neuropsychiatric disorders, except for neurodevelopmental disorders, and severe physical illness.
3. Subjects who can understand this study and give written informed consent. A subject under the age of 20 needs informed consent from a legal representative.
4. Age more than 15 years old.

Key exclusion criteria

1. Subjects who are regarded inappropriate as a participant by attending psychiatrists.
2. Subjects who fall into the followings; cardiac pacemaker, cerebral artery clip, Implanted medical devices (ICD, cochlear implant, nerve stimulator, other), implanted infusion pump, embedded metal in the body, pregnancy or possibly pregnant, tattoos, permanent makeup and so on. These potential risks for MRI scan are screened by Medical Questionnaire for MRI Scan.

Target sample size

400


Research contact person

Name of lead principal investigator

1st name Kato
Middle name
Last name Nobumasa

Organization

Showa University

Division name

Medical Institute of Developmental Disabilities Research

Zip code

157-8577

Address

6-11-11, Kita-karasuyama, Setagaya, Tokyo 157-8577, JAPAN

TEL

0353159357

Email

katon@med.showa-u.ac.jp


Public contact

Name of contact person

1st name Nakamura
Middle name
Last name Motoaki

Organization

Showa University

Division name

Medical Institute of Developmental Disabilities Research

Zip code

157-8577

Address

6-11-11, Kita-karasuyama, Setagaya, Tokyo 157-8577, JAPAN

TEL

0353159357

Homepage URL


Email

motoaki@med.showa-u.ac.jp


Sponsor or person

Institute

Japan Agency for Medical Research and Development (AMED)

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development (AMED)

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Showa University, Karasuyama Hospital

Address

6-11-11, Kita-karasuyama, Setagaya, Tokyo 157-8577, JAPAN

Tel

03-3300-5247

Email

scri@ofc.showa-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 04 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2020 Year 04 Month 10 Day

Date of IRB

2020 Year 04 Month 03 Day

Anticipated trial start date

2020 Year 05 Month 07 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

In this observational study, MRI and clinical / cognitive data are longitudinally collected before and after treatment selected in clinical practice of neurodevelopmental disorders such as ASD and ADHD. MRI data include fMRI, resting-state fMRI, structural MRI and DTI. Clinical / cognitive evaluations include ADOS-2, CAARS, CANTAB and so on.


Management information

Registered date

2020 Year 04 Month 13 Day

Last modified on

2021 Year 12 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045754


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name